An in vivo Car-T produced a 100% response rate – in three patients.

Data will be presented on Kura’s Komzifti and Syndax’s Revuforj in first-line AML.

Rival BTK degraders face off, as do bispecific Cars and T-cell engagers.

Arcellx and AstraZeneca take centre stage.

Five years after settling, GSK is again accused of breaching the Jemperli deal.

Meanwhile, Zai Lab faces delays in its pivotal DLL3 trial. 

The cash-strapped biotech adds Car-T projects but tries to avoid a lawsuit.